Contineum Therapeutics (CTNM) Corporate presentation summary

Strategic focus and pipeline

• PIPE-791, an LPAR1 antagonist, is the lead program for IPF and chronic pain; it is described as a differentiated, brain-penetrant small molecule.

• PIPE-307 is an M1R antagonist for MDD, with further development at Janssen’s sole discretion; development of CTX-343 is deferred pending program-specific funding.

• All assets were internally developed; discovery programs span various undisclosed mechanisms.

• Projected cash runway extends through mid-2029 using existing cash and cash equivalents, expected to support key milestones.

PIPE-791 in IPF

• Global Phase 2 trial plans ~324 subjects randomized 1:1:1; primary endpoint is FVC change from baseline through week 26, with completion estimated for June 2028.

• Regulatory authorizations cover 25 countries; more than 100 sites are activated in 16 countries.

• A 1 mg dose achieved >90% receptor occupancy with once-daily dosing; the program highlights sustained target coverage and no dose titration.

• Phase 1 healthy-volunteer studies reported no dose-limiting AEs or toxicity, notable laboratory changes, or safety observations in vital signs, ECG or telemetry.

• Prior LPAR1 clinical trials included two Phase 2 and one Phase 3 trial in IPF, plus a Phase 3 trial underway in PPF; the estimated IPF market is $4B, with 130K+ US and 3M global patients.

• IP coverage for PIPE-791 extends through 2042.

Chronic pain program

• Phase 1b was a randomized, double-blind, placebo-controlled, 4-week crossover trial of 10 mg once daily in 43 patients: 23 with chronic osteoarthritis pain and 20 with chronic lower back pain.

• Most treatment-emergent AEs were mild to moderate; no serious AEs or meaningful changes in vital signs, blood pressure or clinically relevant orthostatic events were reported.

• Exploratory pain and functional measures showed numerical improvement from baseline, particularly in osteoarthritis pain; PIPE-791 numerically outperformed placebo consistently in that group.

• Results support further evaluation of PIPE-791 for chronic pain.